Clinical Trials Logo

Pseudoexfoliation Glaucoma clinical trials

View clinical trials related to Pseudoexfoliation Glaucoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04609345 Not yet recruiting - Ocular Hypertension Clinical Trials

Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients

Start date: November 2020
Phase:
Study type: Observational

This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide. The study also analyses sub group of OSD prevalence, stratified according to the treatment types (i.e. preserved, preservative-free, and combination of preservative-free and preserved eyedrops), and illustrates the patient perspective on OSD.

NCT ID: NCT04440527 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

PAINT
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

NCT ID: NCT04416724 Not yet recruiting - Clinical trials for Pseudoexfoliation Glaucoma

Phacoemulsification vs SLT as Initial Treatment for Pseudoexfoliation Glaucoma

CANPEX1
Start date: April 2021
Phase: N/A
Study type: Interventional

The Canadian Pseudoexfoliation Glaucoma Study 1 is a randomized clinical trial that aims to compare two initial treatment options - Selective Laser Trabeculoplasty (SLT) and Phacoemulsification (PHACO) - in newly diagnosed patients with pseudoexfoliation and need to lower the intraocular pressure. Patients with pseudoexfoliation and a recent decision to lower the intraocular pressure, who also have early asymptomatic lens opacification will be recruited and randomized to receive either SLT or PHACO. Patients will be followed for 2 years according to a target IOP protocol based on the Canadian Ophthalmological Society Glaucoma guidelines. Patients who do not achieve the target IOP with the initial randomization procedure will receive IOP lowering medications. The main outcome of interest will be the proportion of subjects who need IOP lowering medications after 2 years. Secondary outcomes include IOP reduction, time to need medications, patient reported outcomes in terms of visual function, and occurrence of adverse effects. To obtain longer follow-up information beyond two years, a chart review will be done 5 and 10 years after randomization.